Filing Details
- Accession Number:
- 0001299130-23-000038
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-06 16:46:54
- Reporting Period:
- 2023-03-02
- Accepted Time:
- 2023-03-06 16:46:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1299130 | Pacific Biosciences Of California Inc. | PACB | Laboratory Analytical Instruments (3826) | 161590339 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1825421 | G. Susan Kim | Pacific Biosciences Of California, Inc. 1305 O'Brien Drive Menlo Park CA 94025 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-03-02 | 164,200 | $0.00 | 328,550 | No | 4 | A | Direct | |
Common Stock | Disposition | 2023-03-03 | 5,045 | $9.49 | 323,505 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15th of each of 2024, 2025, 2026, and 2027, provided that the Reporting Person continues to serve through each applicable vesting date.
- Includes 1,769 shares purchased on March 1, 2023 under the Company's 2010 Employee Stock Purchase Plan.
- Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
- This sale price represents the weighted average sale price of the shares sold ranging from $9.24 to $9.71 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.